Cargando…
Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US
BACKGROUND: Insertable cardiac monitors (ICMs) are a clinically effective means of detecting atrial fibrillation (AF) in high-risk patients, and guiding the initiation of non-vitamin K oral anticoagulants (NOACs). Their cost-effectiveness from a US clinical payer perspective is not yet known. The ob...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875401/ https://www.ncbi.nlm.nih.gov/pubmed/36698055 http://dx.doi.org/10.1186/s12872-023-03073-6 |
_version_ | 1784877953025310720 |
---|---|
author | Elkind, Mitchell S. V. Witte, Klaus K. Kasner, Scott E. Sawyer, Laura M. Grimsey Jones, Frank W. Rinciog, Claudia Tsintzos, Stelios Rosemas, Sarah C. Lanctin, David Ziegler, Paul D. Reynolds, Matthew R. |
author_facet | Elkind, Mitchell S. V. Witte, Klaus K. Kasner, Scott E. Sawyer, Laura M. Grimsey Jones, Frank W. Rinciog, Claudia Tsintzos, Stelios Rosemas, Sarah C. Lanctin, David Ziegler, Paul D. Reynolds, Matthew R. |
author_sort | Elkind, Mitchell S. V. |
collection | PubMed |
description | BACKGROUND: Insertable cardiac monitors (ICMs) are a clinically effective means of detecting atrial fibrillation (AF) in high-risk patients, and guiding the initiation of non-vitamin K oral anticoagulants (NOACs). Their cost-effectiveness from a US clinical payer perspective is not yet known. The objective of this study was to evaluate the cost-effectiveness of ICMs compared to standard of care (SoC) for detecting AF in patients at high risk of stroke (CHADS(2) ≥ 2), in the US. METHODS: Using patient data from the REVEAL AF trial (n = 393, average CHADS(2) score = 2.9), a Markov model estimated the lifetime costs and benefits of detecting AF with an ICM or with SoC (specifically intermittent use of electrocardiograms and 24-h Holter monitors). Ischemic and hemorrhagic strokes, intra- and extra-cranial hemorrhages, and minor bleeds were modelled. Diagnostic and device costs, costs of treating stroke and bleeding events and medical therapy—specifically costs of NOACs were included. Costs and health outcomes, measured as quality-adjusted life years (QALYs), were discounted at 3% per annum, in line with standard practice in the US setting. One-way deterministic and probabilistic sensitivity analyses (PSA) were undertaken. RESULTS: Lifetime per-patient cost for ICM was $31,116 versus $25,330 for SoC. ICMs generated a total of 7.75 QALYs versus 7.59 for SoC, with 34 fewer strokes projected per 1000 patients. The model estimates a number needed to treat of 29 per stroke avoided. The incremental cost-effectiveness ratio was $35,528 per QALY gained. ICMs were cost-effective in 75% of PSA simulations, using a $50,000 per QALY threshold, and a 100% probability of being cost-effective at a WTP threshold of $150,000 per QALY. CONCLUSIONS: The use of ICMs to identify AF in a high-risk population is likely to be cost-effective in the US healthcare setting. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-023-03073-6. |
format | Online Article Text |
id | pubmed-9875401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98754012023-01-26 Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US Elkind, Mitchell S. V. Witte, Klaus K. Kasner, Scott E. Sawyer, Laura M. Grimsey Jones, Frank W. Rinciog, Claudia Tsintzos, Stelios Rosemas, Sarah C. Lanctin, David Ziegler, Paul D. Reynolds, Matthew R. BMC Cardiovasc Disord Research BACKGROUND: Insertable cardiac monitors (ICMs) are a clinically effective means of detecting atrial fibrillation (AF) in high-risk patients, and guiding the initiation of non-vitamin K oral anticoagulants (NOACs). Their cost-effectiveness from a US clinical payer perspective is not yet known. The objective of this study was to evaluate the cost-effectiveness of ICMs compared to standard of care (SoC) for detecting AF in patients at high risk of stroke (CHADS(2) ≥ 2), in the US. METHODS: Using patient data from the REVEAL AF trial (n = 393, average CHADS(2) score = 2.9), a Markov model estimated the lifetime costs and benefits of detecting AF with an ICM or with SoC (specifically intermittent use of electrocardiograms and 24-h Holter monitors). Ischemic and hemorrhagic strokes, intra- and extra-cranial hemorrhages, and minor bleeds were modelled. Diagnostic and device costs, costs of treating stroke and bleeding events and medical therapy—specifically costs of NOACs were included. Costs and health outcomes, measured as quality-adjusted life years (QALYs), were discounted at 3% per annum, in line with standard practice in the US setting. One-way deterministic and probabilistic sensitivity analyses (PSA) were undertaken. RESULTS: Lifetime per-patient cost for ICM was $31,116 versus $25,330 for SoC. ICMs generated a total of 7.75 QALYs versus 7.59 for SoC, with 34 fewer strokes projected per 1000 patients. The model estimates a number needed to treat of 29 per stroke avoided. The incremental cost-effectiveness ratio was $35,528 per QALY gained. ICMs were cost-effective in 75% of PSA simulations, using a $50,000 per QALY threshold, and a 100% probability of being cost-effective at a WTP threshold of $150,000 per QALY. CONCLUSIONS: The use of ICMs to identify AF in a high-risk population is likely to be cost-effective in the US healthcare setting. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-023-03073-6. BioMed Central 2023-01-25 /pmc/articles/PMC9875401/ /pubmed/36698055 http://dx.doi.org/10.1186/s12872-023-03073-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Elkind, Mitchell S. V. Witte, Klaus K. Kasner, Scott E. Sawyer, Laura M. Grimsey Jones, Frank W. Rinciog, Claudia Tsintzos, Stelios Rosemas, Sarah C. Lanctin, David Ziegler, Paul D. Reynolds, Matthew R. Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US |
title | Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US |
title_full | Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US |
title_fullStr | Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US |
title_full_unstemmed | Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US |
title_short | Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US |
title_sort | cost-effectiveness of an insertable cardiac monitor in a high-risk population in the us |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875401/ https://www.ncbi.nlm.nih.gov/pubmed/36698055 http://dx.doi.org/10.1186/s12872-023-03073-6 |
work_keys_str_mv | AT elkindmitchellsv costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus AT witteklausk costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus AT kasnerscotte costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus AT sawyerlauram costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus AT grimseyjonesfrankw costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus AT rinciogclaudia costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus AT tsintzosstelios costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus AT rosemassarahc costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus AT lanctindavid costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus AT zieglerpauld costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus AT reynoldsmatthewr costeffectivenessofaninsertablecardiacmonitorinahighriskpopulationintheus |